SCHEMBL4797641

SCHEMBL4797641

Clc1nc(SCc2ccccc2)ns1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
ALOX15 P16050 2/20 0.66
HSD17B10 Q99714 2/20 0.50
NPC1 O15118 1/20 0.49
NPSR1 Q6W5P4 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
PAK4 O96013 1/20 0.47
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
MAPT P10636 2/20 0.44
HSP90AA1 P07900 1/20 0.44
CYP3A4 P08684 1/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 2/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL27339379 0.87 RAB9A (0.52) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL4798493 0.86 L3MBTL1 (0.59) RAB9ASMN1; SMN2ALOX15NPC1NPSR1
SCHEMBL4798776 0.84 TOP2A (0.49) RAB9ASMN1; SMN2ALOX15TDP1ALDH1A1
SCHEMBL4797109 0.83 RAB9A (0.51) RAB9ASMN1; SMN2ALOX15NPSR1TDP1
SCHEMBL4798511 0.80 KMT2A (0.58) RAB9ASMN1; SMN2NPC1TDP1ALDH1A1
SCHEMBL4799594 0.80 RAB9A (0.50) RAB9ASMN1; SMN2ALOX15NPC1NPSR1
SCHEMBL4795635 0.80 RAB9A (0.43) RAB9ASMN1; SMN2ALOX15NPC1PAK4
SCHEMBL4795272 0.79 MAPT (0.42) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL10535559 0.79 RAB9A (1.00) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL4797136 0.79 MAPT (0.49) RAB9ASMN1; SMN2ALOX15NPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
CN-1321117-C Thiadiazole compound and use thereof SUMITOMO CHEMICAL CO (JP) 2007-06-13 CN disclosed
US-20060014962-A1 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-01-19 US disclosed
CN-1703413-A Thiadiazole compound and use thereof SUMITOMO CHEMICAL CO (JP) 2005-11-30 CN disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1550661-A1 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-07-06 EP disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed
EP-0619805-B1 5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS PFIZER (US) 2000-03-15 EP disclosed
US-5639752-A SEROTONIN AGONIST PFIZER INC (US) 1997-06-17 US disclosed
EP-0619805-A1 INDOLE DERIVATIVES PFIZER HOSPITAL PRODUCTS, INC. (US) 1994-10-19 EP disclosed
WO-1993011106-A1 INDOLE DERIVATIVES PFIZER, INC. (US) 1993-06-10 WO disclosed
US-4455428-A HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1984-06-19 US disclosed
EP-0081730-A1 Process for the preparation of hetaryloxyacetamides BAYER AG (DE) 1983-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH RAB9A 1998/4885SMN1; SMN2 3880/4885ALOX15 940/4885
US-20060014962-A1 Thiadiazole compound and use thereof CBR3, TH, CYP2E1 RAB9A 1437/4885SMN1; SMN2 3070/4885ALOX15 537/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH RAB9A 2211/4885SMN1; SMN2 3891/4885ALOX15 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.